Drug intelligence / Profile preview

Anti-angiogenesis Peptide

Development stage: Preclinical
Lead developer: Peking University Cancer Hospital & Institute
Modality: Peptides
Administration: Ophthalmic

Overview

Anti-angiogenesis Peptide (血管生成抑肽) is a peptide-based therapeutic candidate currently in preclinical development by Beijing Sciecure Pharmaceutical (赛升药业). It is specifically designed for the treatment of choroidal neovascularization (CNV), a pathological condition characterized by the growth of abnormal, leaky blood vessels in the choroid layer of the eye, which can lead to severe vision loss in diseases such as wet age-related macular degeneration. As an anti-angiogenic agent, this peptide is intended to inhibit the signaling pathways that drive the formation of these pathological vessels, thereby preserving retinal structure and function.

Other names: 血管生成抑肽Anti-angiogenic peptide

Beyond the preview

Go deeper on Anti-angiogenesis Peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-angiogenesis Peptide.

Explore the full profile